Anthrax Vaccine Plan: VaxGen, Avecia To Produce 4,000 Test Doses In March
Executive Summary
VaxGen and Avecia each expect to produce 2,000 test doses of recombinant anthrax vaccine by the end of March under separate contracts with NIH's National Institute of Allergy & Infectious Diseases
You may also be interested in...
Anthrax Vaccine Timetable Is Reasonable, GAO Finds; Aventis Protest Denied
HHS' next-generation anthrax vaccine development deadlines are reasonable, the General Accounting Office said in a rejection of an Aventis-Pasteur protest
Anthrax Vaccine Timetable Is Reasonable, GAO Finds; Aventis Protest Denied
HHS' next-generation anthrax vaccine development deadlines are reasonable, the General Accounting Office said in a rejection of an Aventis-Pasteur protest
Next-Gen Smallpox, Anthrax Vaccines To Be First Use Of Animal Efficacy
A next-generation smallpox vaccine is expected to be the first product licensed under FDA's animal efficacy rule, HHS Office of the Assistant Secretary for Public Health Emergency Preparedness Senior Advisor Philip Russell, MD, said Aug. 28